CheckMate 141: 1‐Year Update and Subgroup Analysis of Nivolumab as First‐Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

Por Gillison, Maura L., Blumenschein, George, Fayette, Jerome, Guigay, Joel, Colevas, A. Dimitrios, Licitra, Lisa, Harrington, Kevin J., Kasper, Stefan, Vokes, Everett E., Even, Caroline, Worden, Francis, Saba, Nabil F., Iglesias Docampo, Lara Carmen, Haddad, Robert, Rordorf, Tamara, Kiyota, Naomi, Tahara, Makoto, Monga, Manish, Lynch, Mark, Li, Li, Ferris, Robert L.
Publicado no Oncologist (2018)

Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung c...

Por Garon, Edward B, Scagliotti, Giorgio Vittorio, Gautschi, Oliver, Reck, Martin, Thomas, Michael, Iglesias Docampo, Lara, Kalofonos, Haralabos, Kim, Joo-Hang, Gans, Steven, Brustugun, Odd Terje, Orlov, Sergey V, Cuyun Carter, Gebra, Zimmermann, Annamaria H, Oton, Ana B, Alexandris, Ekaterine, Lee, Pablo, Wolff, Katharina, Stefaniak, Victoria Jennifer, Socinski, Mark A, Pérol, Maurice
Publicado no ESMO Open (2020)